---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004202"
form_type: "8-K"
ticker: "ANEB"
cik: "0001815974"
company_name: "Anebulo Pharmaceuticals, Inc."
filed_at: "2023-02-10T23:59:59+00:00"
generated_at: "2026-06-19T18:14:14.770770+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Anebulo reports Q2 fiscal 2023 net loss of $3.8M; Phase 2 trial completed for ANEB-001

## Summary
- Net loss of $3.8M ($0.15 per share) vs $1.1M ($0.05) in Q2 fiscal 2022.
- Cash and cash equivalents of $16.4M as of Dec 31, 2022.
- Completed dosing Phase 2 trial for ANEB-001; preliminary data shows 10mg dose reduces key ACI symptoms.
- Final Phase 2 data expected by end Q1 2023; End-of-Phase 2A meeting with FDA expected Q2 2023.
- Continued development of parenteral formulation of ANEB-001.

## SEC filing metadata
- accession: 0001493152-23-004202
- form_type: 8-K
- ticker: ANEB
- cik: 0001815974
- company_name: Anebulo Pharmaceuticals, Inc.
- filed_at: 2023-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/0001493152-23-004202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004202
- JSON: https://secwatch.observer/filing/0001493152-23-004202.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004202.txt

## Key facts
- Earnings Releases
  Anebulo Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: net income ($3.8 million), EPS $(0.15).
  - Period: three months ended December 31, 2022
  - Net income: ($3.8 million)
  - EPS: $(0.15)
  - Result: reported results
  source text: Net loss in the second quarter of fiscal 2023 was $3.8 million, or $(0.15) per share, compared with a net loss of $1.1 million, or $(0.05) per share, in the second quarter of fiscal 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/0001493152-23-004202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.